Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors

Angela S. Carlson; Huarui Cui; Anand Divakaran; Jorden A. Johnson; Ryan M. Brunner; William C.K. Pomerantz; Joseph J. Topczewski

doi:10.1021/acsmedchemlett.9b00227

Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors

Angela S. Carlson, Huarui Cui, Anand Divakaran, Jorden A. Johnson, Ryan M. Brunner, William C.K. Pomerantz, Joseph J. Topczewski

Chemistry (Twin Cities)

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The Bromodomain and Extra Terminal (BET) family of proteins recognize post-translational N-ϵ-acetylated lysine modifications, regulating transcription as "reader" proteins. Bromodomain inhibitors are interesting targets for the development of potential cancer, inflammation, and heart disease treatments. Several dual kinase-bromodomain inhibitors have been identified by screening kinase inhibitor libraries against BET proteins. Although potentially useful from a polypharmacology standpoint, multitarget binding complicates deciphering molecular mechanisms. This report describes a systematic approach to mitigating kinase activity in a dual kinase-bromodomain inhibitor based on a 1,2,3-triazole-pyrimidine core. By modifying the triazole substituent and altering the pyrimidine core, this structure-activity relationship study enhanced BET activity while reducing the p38α kinase activity >90,000-fold. A BRD4-D1 cocrystal structure indicates that the 1,2,3-triazole is acting as a N-ϵ-acetylated lysine mimic. A BRD4 sensitive cell line, MM.1S, was used to demonstrate activity in cells, which is further supported by reduced c-Myc expression.

Original language	English (US)
Pages (from-to)	1296-1301
Number of pages	6
Journal	ACS Medicinal Chemistry Letters
Volume	10
Issue number	9
DOIs	https://doi.org/10.1021/acsmedchemlett.9b00227
State	Published - Sep 12 2019

Bibliographical note

Funding Information:
We acknowledge Daniel A. Harki for his helpful discussions during this project. MM.1S cells were a gift from Dr. Brian Van Ness at the University of Minnesota. This work was supported by the NIGMS (Grant R35GM124718), the American Cancer Society (# 129819-IRG-16-189-58-IRG88), the University of Minnesota Masonic Cancer Center (Pre-R01 pilot grant), and the University of Minnesota. J.J. was supported by a National Institutes of Health Biotechnology training grant 5T32GM008347-23. A.D. was supported by the NIH chemistry–biology interface training grant at the University of Minnesota, 5T32GM008700-18.

Publisher Copyright:
Copyright © 2019 American Chemical Society.

Keywords

BET
BRD4
Bromodomains
kinases
p38α

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1021/acsmedchemlett.9b00227

OpenUrl availability

Full text

Cite this

@article{b0e354d0669b4ef78a4ac7a3a0308115,

title = "Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors",

abstract = "The Bromodomain and Extra Terminal (BET) family of proteins recognize post-translational N-ϵ-acetylated lysine modifications, regulating transcription as {"}reader{"} proteins. Bromodomain inhibitors are interesting targets for the development of potential cancer, inflammation, and heart disease treatments. Several dual kinase-bromodomain inhibitors have been identified by screening kinase inhibitor libraries against BET proteins. Although potentially useful from a polypharmacology standpoint, multitarget binding complicates deciphering molecular mechanisms. This report describes a systematic approach to mitigating kinase activity in a dual kinase-bromodomain inhibitor based on a 1,2,3-triazole-pyrimidine core. By modifying the triazole substituent and altering the pyrimidine core, this structure-activity relationship study enhanced BET activity while reducing the p38α kinase activity >90,000-fold. A BRD4-D1 cocrystal structure indicates that the 1,2,3-triazole is acting as a N-ϵ-acetylated lysine mimic. A BRD4 sensitive cell line, MM.1S, was used to demonstrate activity in cells, which is further supported by reduced c-Myc expression.",

keywords = "BET, BRD4, Bromodomains, kinases, p38α",

author = "Carlson, {Angela S.} and Huarui Cui and Anand Divakaran and Johnson, {Jorden A.} and Brunner, {Ryan M.} and Pomerantz, {William C.K.} and Topczewski, {Joseph J.}",

note = "Funding Information: We acknowledge Daniel A. Harki for his helpful discussions during this project. MM.1S cells were a gift from Dr. Brian Van Ness at the University of Minnesota. This work was supported by the NIGMS (Grant R35GM124718), the American Cancer Society (# 129819-IRG-16-189-58-IRG88), the University of Minnesota Masonic Cancer Center (Pre-R01 pilot grant), and the University of Minnesota. J.J. was supported by a National Institutes of Health Biotechnology training grant 5T32GM008347-23. A.D. was supported by the NIH chemistry–biology interface training grant at the University of Minnesota, 5T32GM008700-18. Publisher Copyright: Copyright {\textcopyright} 2019 American Chemical Society.",

year = "2019",

month = sep,

day = "12",

doi = "10.1021/acsmedchemlett.9b00227",

language = "English (US)",

volume = "10",

pages = "1296--1301",

journal = "ACS Medicinal Chemistry Letters",

issn = "1948-5875",

publisher = "American Chemical Society",

number = "9",

}

TY - JOUR

T1 - Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors

AU - Carlson, Angela S.

AU - Cui, Huarui

AU - Divakaran, Anand

AU - Johnson, Jorden A.

AU - Brunner, Ryan M.

AU - Pomerantz, William C.K.

AU - Topczewski, Joseph J.

N1 - Funding Information: We acknowledge Daniel A. Harki for his helpful discussions during this project. MM.1S cells were a gift from Dr. Brian Van Ness at the University of Minnesota. This work was supported by the NIGMS (Grant R35GM124718), the American Cancer Society (# 129819-IRG-16-189-58-IRG88), the University of Minnesota Masonic Cancer Center (Pre-R01 pilot grant), and the University of Minnesota. J.J. was supported by a National Institutes of Health Biotechnology training grant 5T32GM008347-23. A.D. was supported by the NIH chemistry–biology interface training grant at the University of Minnesota, 5T32GM008700-18. Publisher Copyright: Copyright © 2019 American Chemical Society.

PY - 2019/9/12

Y1 - 2019/9/12

N2 - The Bromodomain and Extra Terminal (BET) family of proteins recognize post-translational N-ϵ-acetylated lysine modifications, regulating transcription as "reader" proteins. Bromodomain inhibitors are interesting targets for the development of potential cancer, inflammation, and heart disease treatments. Several dual kinase-bromodomain inhibitors have been identified by screening kinase inhibitor libraries against BET proteins. Although potentially useful from a polypharmacology standpoint, multitarget binding complicates deciphering molecular mechanisms. This report describes a systematic approach to mitigating kinase activity in a dual kinase-bromodomain inhibitor based on a 1,2,3-triazole-pyrimidine core. By modifying the triazole substituent and altering the pyrimidine core, this structure-activity relationship study enhanced BET activity while reducing the p38α kinase activity >90,000-fold. A BRD4-D1 cocrystal structure indicates that the 1,2,3-triazole is acting as a N-ϵ-acetylated lysine mimic. A BRD4 sensitive cell line, MM.1S, was used to demonstrate activity in cells, which is further supported by reduced c-Myc expression.

AB - The Bromodomain and Extra Terminal (BET) family of proteins recognize post-translational N-ϵ-acetylated lysine modifications, regulating transcription as "reader" proteins. Bromodomain inhibitors are interesting targets for the development of potential cancer, inflammation, and heart disease treatments. Several dual kinase-bromodomain inhibitors have been identified by screening kinase inhibitor libraries against BET proteins. Although potentially useful from a polypharmacology standpoint, multitarget binding complicates deciphering molecular mechanisms. This report describes a systematic approach to mitigating kinase activity in a dual kinase-bromodomain inhibitor based on a 1,2,3-triazole-pyrimidine core. By modifying the triazole substituent and altering the pyrimidine core, this structure-activity relationship study enhanced BET activity while reducing the p38α kinase activity >90,000-fold. A BRD4-D1 cocrystal structure indicates that the 1,2,3-triazole is acting as a N-ϵ-acetylated lysine mimic. A BRD4 sensitive cell line, MM.1S, was used to demonstrate activity in cells, which is further supported by reduced c-Myc expression.

KW - BET

KW - BRD4

KW - Bromodomains

KW - kinases

KW - p38α

UR - http://www.scopus.com/inward/record.url?scp=85070800751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070800751&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.9b00227

DO - 10.1021/acsmedchemlett.9b00227

M3 - Article

C2 - 31531200

AN - SCOPUS:85070800751

SN - 1948-5875

VL - 10

SP - 1296

EP - 1301

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 9

ER -

Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this